Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Isoleucine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.34 |
| ▸ | GRIK1 | P39086 | 9/20 | 0.32 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.32 |
| ▸ | GRIK3 | Q13003 | 3/20 | 0.32 |
| ▸ | GRIK5 | Q16478 | 3/20 | 0.32 |
| ▸ | GRIK2 | Q13002 | 5/20 | 0.32 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.31 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.30 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.30 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.30 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isoleucine SCHEMBL19813749 | 1.00 | SLC7A5 (0.40) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Isoleucine SCHEMBL4611263 | 0.97 | SLC7A5 (0.38) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Isoleucine SCHEMBL388791 | 0.96 | SLC1A3 (0.37) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Isoleucine SCHEMBL27709387 | 0.96 | SLC1A3 (0.37) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Isoleucine SCHEMBL23645012 | 0.95 | SLC7A5 (0.44) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Isoleucine SCHEMBL20913231 | 0.95 | SLC7A5 (0.44) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Isoleucine SCHEMBL20913222 | 0.95 | SLC7A5 (0.44) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Isoleucine SCHEMBL20913224 | 0.95 | SLC7A5 (0.44) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Isoleucine SCHEMBL20913227 | 0.95 | SLC7A5 (0.44) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Isoleucine SCHEMBL386322 | 0.95 | SLC7A5 (0.44) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241176-A1 | COMPOSITION FOR TREATING OR SENSITIZING INTERFERON BETA RESISTANT CANCER DISEASE COMPRISING CFLIP SIRNA | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2023-08-03 | — | — | US | claimed |
| EP-3492107-B1 | COMPOSITION FOR TREATING OR SENSITIZING INTERFERON BETA RESISTANT CANCER DISEASE COMPRISING CFLIP SIRNA | ABION INC (KR) | 2022-12-21 | — | — | EP | claimed |
| US-20210299225-A1 | COMPOSITION FOR TREATING OR SENSITIZING INTERFERON BETA RESISTANT CANCER DISEASE COMPRISING CFLIP SIRNA | ABION INC. (KR) | 2021-09-30 | — | — | US | claimed |
| EP-3492107-A1 | COMPOSITION FOR TREATING OR SENSITIZING INTERFERON BETA RESISTANT CANCER DISEASE COMPRISING CFLIP SIRNA | Abion Inc. (KR) | 2019-06-05 | — | — | EP | claimed |
| US-8101716-B2 | Human interferon-beta mutein | Shin, Young Kee (KR) | 2012-01-24 | — | — | US | claimed |
| EP-1809661-B1 | HUMAN INTERFERON-BETA MUTEIN | SHIN YOUNG KEE (KR) | 2011-05-18 | — | — | EP | claimed |
| US-20100003721-A1 | HUMAN INTERFERON-BETA MUTEIN | Shin, Young Kee (KR) | 2010-01-07 | — | — | US | claimed |
| US-20230241176-A1 | COMPOSITION FOR TREATING OR SENSITIZING INTERFERON BETA RESISTANT CANCER DISEASE COMPRISING CFLIP SIRNA | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2023-08-03 | — | — | US | disclosed |
| US-20230241176-A1 | COMPOSITION FOR TREATING OR SENSITIZING INTERFERON BETA RESISTANT CANCER DISEASE COMPRISING CFLIP SIRNA | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2023-08-03 | — | — | US | disclosed |
| CN-109890425-B | Compositions comprising CFLIP SIRNA for treating or sensitizing interferon beta resistant cancer disorders | 瑷备恩有限公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-109890425-B | Compositions comprising CFLIP SIRNA for treating or sensitizing interferon beta resistant cancer disorders | 瑷备恩有限公司 | 2023-05-02 | — | — | CN | disclosed |
| EP-3492107-B1 | COMPOSITION FOR TREATING OR SENSITIZING INTERFERON BETA RESISTANT CANCER DISEASE COMPRISING CFLIP SIRNA | ABION INC (KR) | 2022-12-21 | — | — | EP | disclosed |
| EP-4012030-A1 | COMPOSITION FOR TREATING OR SENSITIZING INTERFERON BETA RESISTANT CANCER DISEASE COMPRISING CFLIP SIRNA | Abion Inc. (KR) | 2022-06-15 | — | — | EP | disclosed |
| EP-3266801-A1 | HUMAN INTERFERON-BETA VARIANT CONJUGATED IMMUNOCYTOKINE AND METHOD FOR PREPARING SAME | Abion Inc. (KR) | 2018-01-10 | — | — | EP | disclosed |
| US-8101716-B2 | Human interferon-beta mutein | Shin, Young Kee (KR) | 2012-01-24 | — | — | US | disclosed |
| EP-1809661-B1 | HUMAN INTERFERON-BETA MUTEIN | SHIN YOUNG KEE (KR) | 2011-05-18 | — | — | EP | disclosed |
| US-20100003721-A1 | HUMAN INTERFERON-BETA MUTEIN | Shin, Young Kee (KR) | 2010-01-07 | — | — | US | disclosed |
| EP-1809661-A4 | HUMAN INTERFERON-BETA MUTEIN | SHIN YOUNG KEE (KR) | 2008-02-06 | — | — | EP | disclosed |
| EP-1809661-A1 | HUMAN INTERFERON-BETA MUTEIN | Shin, Young Kee (KR) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006049423-A1 | HUMAN INTERFERON-BETA MUTEIN | SAMSUNG FINE CHEMICALS CO LTD (KR) | 2006-05-11 | — | — | WO | disclosed |